Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice

被引:35
作者
Migrenne, Stephanie [1 ]
Lacombe, Amelie [1 ]
Lefevre, Anne-Laure [1 ]
Pruniaux, Marie-Pierre [2 ]
Guillot, Etienne [2 ]
Galzin, Anne-Marie [2 ]
Magnan, Christophe [1 ]
机构
[1] Univ Paris Diderot, CNRS, F-75205 Paris 13, France
[2] Sanofi Aventis Res & Dev, Rueil Malmaison, France
关键词
endocannabinoid system; cannabinoid receptor 1 antagonist; metabolic syndrome; CB1 RECEPTOR ANTAGONIST; METABOLIC RISK-FACTORS; ENDOCANNABINOID SYSTEM; OVERWEIGHT PATIENTS; ADIPOSE-TISSUE; RESISTANCE; RATS; SR141716; ADIPOCYTES; ACTIVATION;
D O I
10.1152/ajpregu.90824.2008
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Migrenne S, Lacombe A, Lefevre AL, Pruniaux MP, Guillot E, Galzin AM, Magnan C. Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 296: R929-R935, 2009. First published February 11, 2009; doi:10.1152/ajpregu.90824.2008.-The increase in adiponectin levels in obese patients with untreated dyslipidemia and its mRNA expression in adipose tissue of obese animals are one of the most interesting consequences of rimonabant treatment. Thus, part of rimonabant's metabolic effects could be related to an enhancement of adiponectin secretion and its consequence on the modulation of insulin action, as well as energy homeostasis. The present study investigated the effects of rimonabant in adiponectin knockout mice (Ad(-/-)) exposed to diet-induced obesity conditions. Six-week-old Ad(-/-) male mice and their wild-type littermate controls (Ad(+/+)) were fed a high-fat diet for 7 mo. During the last month, animals were administered daily either with vehicle or rimonabant by mouth (10 mg/kg). High-fat feeding induced weight gain by about 130% in both wild-type and Ad(-/-) mice. Obesity was associated with hyperinsulinemia and insulin resistance. Treatment with rimonabant led to a significant and similar decrease in body weight in both Ad(+/+) and Ad(-/-) mice compared with vehicle-treated animals. In addition, rimonabant significantly improved insulin sensitivity in Ad(-/-) mice compared with Ad(-/-) vehicle-treated mice by decreasing hepatic glucose production and increasing glucose utilization index in both visceral and subcutaneous adipose tissue. In contrast, rimonabant failed to improve insulin sensitivity in Ad(+/+) mice, despite the loss in body weight. Rimonabant's effect on body weight appeared independent of the adiponectin pathway, whereas adiponectin seems required to mediate rimonabant- induced improvement of insulin sensitivity in rodents.
引用
收藏
页码:R929 / R935
页数:7
相关论文
共 34 条
[1]   The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells [J].
Bensaid, M ;
Gary-Bobo, M ;
Esclangon, A ;
Maffrand, JP ;
Le Fur, G ;
Oury-Donat, F ;
Soubrié, P .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :908-914
[2]   Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity [J].
Blueher, Matthias ;
Engeli, Stefan ;
Kloeting, Nora ;
Berndt, Janin ;
Fasshauer, Mathias ;
Batkai, Sandor ;
Pacher, Pal ;
Schoen, Michael R. ;
Jordan, Jens ;
Stumvoll, Michael .
DIABETES, 2006, 55 (11) :3053-3060
[3]   Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet [J].
Burcelin, M ;
Crivelli, V ;
Dacosta, A ;
Roy-Tirelli, A ;
Thorens, B .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 282 (04) :E834-E842
[4]   The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects [J].
Buzzetti, R. ;
Petrone, A. ;
Zavarella, S. ;
Zampetti, S. ;
Spoletini, M. ;
Potenziani, S. ;
Leto, G. ;
Osborn, J. ;
Leonetti, F. .
INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 (03) :424-428
[5]   Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia [J].
Despres, JP ;
Golay, A ;
Sjostrom, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2121-2134
[6]   Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats [J].
Doyon, Christian ;
Denis, Raphael G. ;
Baraboi, Elena-Dana ;
Samson, Pierre ;
Lalonde, Jose ;
Deshaies, Yves ;
Richard, Denis .
DIABETES, 2006, 55 (12) :3403-3410
[7]   Activation of the peripheral endocannabinoid system in human obesity [J].
Engeli, S ;
Böhnke, J ;
Feldpausch, M ;
Gorzelniak, K ;
Janke, J ;
Bátkai, S ;
Pacher, P ;
Harvey-White, J ;
Luft, FC ;
Sharma, AM ;
Jordan, J .
DIABETES, 2005, 54 (10) :2838-2843
[8]   Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice [J].
Hao, SZ ;
Avraham, Y ;
Mechoulam, R ;
Berry, EM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 392 (03) :147-156
[9]   Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats [J].
Herling, Andreas W. ;
Kilp, Susanne ;
Elvert, Ralf ;
Haschke, Guido ;
Kramer, Werner .
ENDOCRINOLOGY, 2008, 149 (05) :2557-2566
[10]   Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats [J].
Jamshidi, N ;
Taylor, DA .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (06) :1151-1154